Loading stock data…
IMVT
$27.12-0.02 (-0.09%)
Market ClosedLast close May 1
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunovant, Inc. in the Healthcare sector is trading at $27.12. The stock is currently near its 52-week high of $30.09, remaining 22.1% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why IMVT maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$27.12
Potential Upside
5%
Whystock Fair Value$28.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$40.29+48.6%
Range$22.00 – $66.00
Fundamentals
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating pol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.07%
Volume
Today's trading volume
929,794
Recent News
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?
Roivant Sciences recently reported past topline Phase 3 results showing that Immunovant’s batoclimab did not meet the primary endpoint in thyroid eye disease, while also announcing that Priovant has begun a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, alongside ongoing late-stage programs and an FDA Priority Review for dermatomyositis. This mix of pipeline expansion into an underserved inflammatory scalp disorder with no approved therapies, coupled with regulatory...
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an
Sector Update: Health Care Stocks Softer Thursday Afternoon
Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.6% and the St
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expand